Core Insights - BNY Mellon has introduced 134 digital employees that operate continuously without breaks, distinguishing them from traditional AI agents [1][2] - The bank processes between $2.5 trillion to $3 trillion in daily settlements, with digital employees handling specific repetitive tasks to enhance human productivity [3][5] - BNY Mellon has invested nearly $4 billion in technology in 2025, representing 19% of its total revenue, the highest among large banking peers [9] Digital Employees - Digital employees at BNY are designed to perform specific tasks, such as identifying and fixing errors in payment processing, which were previously handled by humans [4][5] - The bank is not merely replacing human roles but is focusing on upskilling its workforce to be AI literate, with 99% of employees completing a training program named Eliza [6][7] AI Integration and Training - BNY has developed a platform called Eliza that integrates various AI models with internal data and compliance [6] - The bank aims to train 15,000 employees through an AI boot camp this year, focusing on automating tasks that previously took significant time [12][13] Future Outlook - BNY envisions a future where humans and machines work together, emphasizing productivity rather than job replacement [15][16] - The bank currently has 160 AI solutions in production, indicating a strong commitment to leveraging technology for operational efficiency [14]

Core Insights - The race among Wall Street firms to implement AI agents for end-to-end task management is intensifying, with BNY integrating Google Cloud's agentic AI technology into its internal AI platform, Eliza [1][6] Group 1: AI Integration and Functionality - BNY is embedding Google's Gemini 3 into Eliza, which already utilizes multiple large language models, aiming to enhance employee efficiency in daily tasks [2][6] - The integration of agentic AI is expected to streamline tedious processes like client onboarding by breaking tasks into smaller components and orchestrating workflows [2][3] - Gemini 3 can interpret various data formats, including text, images, tables, PDFs, and audio, allowing for a comprehensive analysis of mixed financial materials [3] Group 2: AI Development and Training - BNY's generative AI initiatives accelerated in 2023, with Eliza now supporting over 120 automated tasks, and nearly all employees have completed training in generative and responsible AI [4] - The bank's CEO highlighted the deployment of over 100 "digital employees" working alongside staff on tasks such as payment validations and code repairs, emphasizing the significant AI opportunity [5] Group 3: Competitive Positioning - BNY aims to position itself as an early adopter of AI technologies, having previously partnered with OpenAI and deployed an AI supercomputer powered by NVIDIA to enhance processing capabilities [6]

Core Insights - BNY and Google Cloud have announced the integration of Gemini Enterprise into BNY's enterprise AI platform, Eliza, enhancing deep research capabilities for market analysis [1][2] - The integration allows BNY employees to create AI agents that can efficiently process and analyze extensive financial reports and data, automating routine tasks [2][3] - BNY's AI strategy emphasizes accessibility and integration, aiming to deepen analysis and strategic insights for client services [3] Company Overview - BNY is a global financial services company managing $57.8 trillion in assets under custody and $2.1 trillion in assets under management as of September 30, 2025 [5] - The company has a long history of partnering with clients, including over 90% of Fortune 100 companies and nearly all top 100 banks globally [5] - BNY has been recognized among Fortune's World's Most Admired Companies and Fast Company's Best Workplaces for Innovators [6]

Core Insights - The primary barrier to AI adoption is not technological limitations but rather human adoption, cultural factors, and organizational inertia [2][3] - BNY has launched its proprietary AI platform, Eliza, in 2024, aimed at enhancing employee workflows and client service [3][4] - The bank has a history of embracing technological innovation, having integrated computers and the internet into its operations over the past 70 years [4] AI Adoption and Training - Approximately 15,000 BNY employees have created their own AI agents, and the bank is developing around 150 AI-powered solutions [3][5] - Over 1,000 employees have received more than 40 hours of AI training, which encourages them to explore the potential of AI [5][6] - The training program includes practical applications, starting with simple queries and evolving into more complex problem-solving using AI [6] Organizational Culture and Innovation - BNY's CEO emphasizes the importance of a proactive approach to technology adoption to avoid obsolescence [4] - The company aims to create a "flywheel of excitement" around AI adoption, fostering creativity and innovation among employees [6]

Core Insights - BNY Mellon has increased its deployment of artificial intelligence (AI) solutions by 75% in the third quarter, now having 117 AI solutions in production and over 100 AI agents in use [2][3] Group 1: AI Deployment and Impact - The number of AI solutions in production at BNY Mellon at the end of the third quarter was 75% higher than the previous quarter [2] - The AI solutions assist in various tasks such as identifying new business leads, writing code, automating payment processing, accelerating client onboarding, and increasing automation of reconciliation [3] - AI agents work alongside employees on tasks like payment validations and code repairs, aiming to enhance employee capacity for higher-value work [4] Group 2: AI Platform and Adoption - BNY launched the next version of its AI platform, Eliza, which is described as "smarter, faster and easier to use" [4] - In the first year of Eliza's launch, 36% of the bank's employees adopted the platform, with an expected 96% adoption in the first half of 2025 [4] Group 3: Collaboration and Research - BNY Mellon has partnered with Carnegie Mellon University to support AI research and development, focusing on governance, trust, and accountability in AI applications for financial services [5] - The collaboration aims to combine CMU's academic leadership with BNY's market expertise to advance AI research and responsible deployment [6]

Core Insights - BNY Mellon is upgrading its AI platform, Eliza, to enhance employee efficiency and client response times [1][4] - The bank's CEO emphasized that AI is viewed as a capacity generator, with 98% of employees trained on generative AI [2] - BNY Mellon ranks 14th in AI adoption among the top 50 banks, with a significant push to improve its standing [3] Company Developments - The new version of Eliza will enable employees to access data from various sources, including live market data, to improve client service [4] - The upgrade aims to reduce the time needed for developing client briefings from hours to minutes [5] - Employees are already utilizing Eliza for various tasks, such as reconciling transactions and writing code, highlighting the critical nature of AI fluency [8] Industry Context - The banking industry is increasingly adopting AI, with all top 50 banks referencing AI in investor relations documents [3] - However, only six of the tracked banks reported a financial impact from AI, raising questions about the transformation of core banking functions [6] - BNY Mellon employs a "walled garden" approach for training its AI systems while also integrating external models [7]

Summary of Protalix BioTherapeutics Conference Call Company Overview - Protalix BioTherapeutics is a publicly traded company listed on NYSE American, with a unique technology for expressing complex human proteins through plant cells rather than mammalian cells [4][3] - The company has been operational for approximately 30 years [4] Core Products - Protalix has two FDA-approved drugs: - **El Eliza** for the treatment of Gaucher disease, licensed to Pfizer [8][10] - **El Fabrio** for the treatment of Fabry disease, licensed to Kiesi [8][18] - Both drugs are sold through partnerships, with annual sales to Pfizer and Brazil estimated at $22 to $24 million [13][12] Financial Performance - The manufacturing agreement with Pfizer for El Eliza expires in October 2030, with hopes to renegotiate for potential return of the drug [15] - The market for El Fabrio is expected to grow from $2.2 billion last year to $3.2 billion by the end of the decade, with Protalix potentially earning $100 to $120 million in royalties from Kiesi [17][20] - Protalix is currently well-capitalized with approximately $34 million in cash and zero debt [46] Pipeline and Future Prospects - The most advanced pipeline asset is **PRX-115**, targeting uncontrolled severe gout, with a significant patient population in the U.S. [9][36] - The company is exploring additional dosing regimens for its drugs, including a once-a-month option for El Fabrio, which is under review by the EMA [29][30] - Protalix aims to leverage its core competencies in rare renal diseases and is open to collaborations in this area [44] Market Dynamics - The competitive landscape includes other enzyme replacement therapies (ERTs) like Fabrazyme and Replagal, which require more frequent infusions compared to El Fabrio [27][41] - The agreement with Kiesi includes royalties of 15-40% on U.S. sales and 15-35% on international sales, along with potential milestone payments [18][20] Key Takeaways - Protalix's unique plant-based technology offers cost advantages and manufacturing flexibility [5][6] - The company is focused on maintaining operational stability while exploring growth opportunities in its pipeline [14][46] - Upcoming catalysts include the EMA's decision on the new dosing regimen and the initiation of Phase 2 trials for PRX-115 [53]

Core Insights - The article discusses the historical significance and revival of Eliza, the first chatbot created by Joseph Weizenbaum in the 1960s, highlighting its impact on the development of conversational AI [1][3][11] Group 1: Historical Context - Eliza was inspired by the character Eliza Doolittle from George Bernard Shaw's play "Pygmalion," symbolizing transformation and communication skills [1] - The chatbot operated using a script called DOCTOR, mimicking a Rogerian therapist's approach to engage users in conversation [3][6] Group 2: User Interaction - Users often developed emotional attachments to Eliza, perceiving it as empathetic and understanding, despite its lack of true comprehension [6][9] - The interaction style of Eliza led to a phenomenon where users felt that the chatbot genuinely understood their concerns, showcasing the psychological impact of AI on human interaction [4][6] Group 3: Technical Revival - The original Eliza code was believed to be lost until it was rediscovered in 2021 by researchers at Stanford University and MIT [11] - The revival process involved cleaning and debugging the original code, as well as creating a simulator to run it in an environment similar to the 1960s [11][12] - The restored Eliza, which includes a known bug that causes it to crash when numbers are input, has been made available on GitHub for public use [12]

Summary of The Bank of New York Mellon (BK) 2025 Conference Company Overview - **Company**: The Bank of New York Mellon (BK) - **Segment**: BNY Pershing, the largest business within BNY, focusing on Market and Wealth Services - **Key Metrics**: - Serves approximately 1,300 intermediaries globally - Manages around 8 million client accounts - Total assets under management: $2.7 trillion for Pershing and $3 trillion for BNY globally [15][14] Core Strategic Priorities - **Growth Focus**: The primary strategic priority is growth, with an emphasis on positive operating margins [15][16] - **Client Engagement**: BNY aims to differentiate itself by offering a variety of solutions within its ecosystem to help clients grow [16][17] Key Themes from Insight Financial Advisory Conference - **Event Overview**: The conference had over 2,000 attendees and showcased a broader product set from BNY, including asset servicing, investment management, and treasury services [18][19][21] - **Client-Centric Approach**: The event aimed to demonstrate how BNY can better serve wealth managers by introducing more services [22][23] WOVE Platform - **Launch and Purpose**: WOVE was launched to address advisor productivity challenges, with 60% of advisors frustrated by their current technology [24][25] - **Revenue Generation**: In 2024, WOVE generated an incremental $30 million in revenues, with a target of $60 million to $70 million for 2025 [28][30] - **Modular Design**: The platform is designed to be modular, allowing advisors to select specific applications as needed [26][27] AI Integration - **AI Adoption**: Approximately 90% of BNY employees have signed up for the internal AI platform, Eliza, which enhances operational efficiency [40][41] - **Commercial Applications**: AI is being used to streamline processes such as responding to RFPs and enhancing financial planning tools [42][43] - **Future Potential**: AI is expected to play a significant role in transforming client interactions and operational efficiency [46][48] Industry Dynamics - **RIA Consolidation**: The larger RIA firms are growing faster than smaller firms, with 20% of RIAs driving 80% of the growth [59][60] - **Target Clientele**: BNY focuses on billion-dollar-plus RIA firms, which are seen as optimal clients for their services [60][72] - **Breakaway Business**: The breakaway business model is expected to continue, providing opportunities for BNY to capture new clients [62][63] Product Expansion and Alternatives - **Focus on Alternatives**: BNY is working to improve custodial processes for private assets and alternatives, as demand in this area is increasing [73][75] - **Tokenized Assets**: BNY is prepared to custody tokenized assets, anticipating future demand in this area [80][81] Conclusion - **Positive Outlook**: The consolidation in the RIA market and the focus on large firms positions BNY favorably for future growth [66][70]

Financial Data and Key Metrics Changes - The company reported revenues of $53 million for the fiscal year 2024, indicating a strong cash-generating position for a biotech firm [6][29] - Cash at the end of the last quarter was $34.7 million, with projections to approach cash flow positive by the end of 2024 [29][30] Business Line Data and Key Metrics Changes - The first product, El Eliza, has generated approximately $12 million in Brazil, while global sales through Pfizer are only $50 million out of a $1 billion market, indicating commercialization challenges [9][34] - The second product, El Fabrio, is expected to capture 15% to 20% of a $3.1 billion market, potentially generating $130 million to $150 million in sales for Protalix [13][19] Market Data and Key Metrics Changes - The Fabry market was valued at $2.2 billion last year, with expectations for growth to $3.1 billion by 2030 [12][13] - The gout treatment market is projected to be $5.6 billion with a 6.4% CAGR, highlighting significant potential for the PRX-115 product [25] Company Strategy and Development Direction - The company aims to enhance its platform and explore rare renal diseases, while also focusing on the development of PRX-115 for gout treatment [28][30] - A strategic partnership with Chiesi is crucial, with a tiered royalty agreement that could yield significant revenue based on sales performance [14][18] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges in commercialization for El Eliza but remains optimistic about future partnerships to improve market penetration [10][34] - The company believes that by 2030, total sales could reach between $120 million to $230 million, contingent on successful product launches and market acceptance [35] Other Important Information - The company has no debt and has cleaned its balance sheet, positioning itself for a fresh start [30] - Management noted that the share price drop following the first quarter results was disproportionate and attributed it to market reactions rather than operational failures [31][34] Q&A Session Summary Question: Is it reasonable to liken the competitive advantage of PRX-115 to that of El Fabrio? - Management believes PRX-115 could represent an even stronger competitive advantage due to its potential dosing regimen, which could significantly reduce treatment frequency compared to existing therapies [37] Question: What are the implications of sales fluctuations? - Sales are highly dependent on shipment logistics, and even minor delays can impact revenue recognition, but the company remains optimistic about profitability [38] Question: What are the expected costs for the upcoming trials? - The projected costs for the trials are manageable, estimated at around $24 million over two and a half years, which is significantly lower than previous trials [39]